The eIND: Good Theory, Little Substance
Executive Summary
Biotechs, by all logic, should be embracing the FDA's exploratory IND program, which theoretically allows companies to test compounds in humans with far less than the usual amount of preclinical data. They're not. The program favors large companies-and mostly those racing to develop chronic care treatments in hotly contested areas.